Bob
Wassman

At MARAbio, the bet is simple to state and hard to prove: some autism is autoimmune. Specifically, that during pregnancy a subset of mothers produce autoantibodies that cross the placenta, react with proteins in the developing fetal brain, and shape neurodevelopment. The company calls it maternal autoantibody-related autism - MARA - and it is building a maternal blood test to find it.

Bob Wassman is the person responsible for turning that hypothesis into something a clinic can actually order. As Chief Medical Officer and Executive Vice President of Clinical Development, he owns the unglamorous, decisive part of the work: designing the studies, defining what a result means, and shepherding a frontier idea through the gauntlet of clinical validation. It is the exact job he has done, again and again, for four decades.

The appeal, for him, is the part most people would find daunting. A maternal blood test that flags risk before symptoms is the kind of translation he has spent a career chasing: take something true in a research lab and make it useful at a bedside. MARAbio sits at the intersection of his oldest interests - reproductive medicine, neurodevelopment, and biomarker-based diagnostics - which is to say it reads less like a new job than a culmination.

The science MARAbio is building on grew out of work tying maternal autoantibodies to a measurable share of autism cases. Wassman's contribution is to insist on the discipline that separates a promising correlation from a test a physician can trust: what cutoff counts as positive, how a result should be explained to a family, what a clinician is meant to do next. Those are not footnotes. They are the difference between an interesting paper and a tool that changes a life, and they are precisely the questions he has answered at company after company.

He grew up in Larchmont, New York, close enough to the water that the ocean became a lifelong habit - surfing, sailing, swimming. The pull toward marine biology came first, and it left a mark on his undergraduate work at Yale, where he published research on the alga Codium fragile, a fast-spreading invasive seaweed nicknamed, with some affection, "sputnik weed."

Then biology got more personal. A college friend living with cystic fibrosis turned an abstract interest in genetics into a reason to go to medicine. At Yale he studied under Frank Ruddle, one of the founders of human gene mapping. The mentors that followed read like a genetics hall of fame: Victor McKusick, David Rimoin, Michael Kaback, George Church. He went on to Albany Medical College for his M.D., then board certification in both pediatrics and medical genetics, with later credentials in managed health care from Harvard and medical genetics from UCLA.

The shape of his career was set early: a scientist comfortable at the edge of what is known, trained by the people who drew the first maps, and motivated by a face rather than a footnote.

Ask Wassman about diagnosis and he reaches for an old parable. Several blind men touch an elephant; one feels the trunk and declares it a snake, another the leg and declares it a tree. Each is honest. Each is wrong. His point is humility: a single test, a single observation, a single expert can mistake a fragment for the whole, and medicine is full of people certain about the part they happen to be holding.

That conviction shows up in small, practical habits. He argues for involving spouses and caretakers in medical interactions, on the theory that the person across the desk is not the only one who needs to understand and decide. At TREND Community, where he is also chief medical officer, he has worked on using AI, machine learning and natural-language processing to read what patients say in online communities - a way of listening at scale, sorting signal from noise in the messy, human record of rare disease.

It is a coherent worldview for a man who keeps choosing frontier problems. If no one tool sees the whole elephant, the answer is more vantage points, more voices, and a healthy suspicion of your own certainty.